

# Kari M Morrissey

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1928670/publications.pdf>

Version: 2024-02-01

6  
papers

440  
citations

1684188

5  
h-index

2053705

5  
g-index

6  
all docs

6  
docs citations

6  
times ranked

799  
citing authors

#	ARTICLE	IF	CITATIONS
1	Phase I Study of the Indoleamine 2,3-Dioxygenase 1 (IDO1) Inhibitor Navoximod (GDC-0919) Administered with PD-L1 Inhibitor (Atezolizumab) in Advanced Solid Tumors. <i>Clinical Cancer Research</i> , 2019, 25, 3220-3228.	7.0	179
2	Phase Ia study of the indoleamine 2,3-dioxygenase 1 (IDO1) inhibitor navoximod (GDC-0919) in patients with recurrent advanced solid tumors. , 2018, 6, 61.		106
3	Alternative dosing regimens for atezolizumab: an example of model-informed drug development in the postmarketing setting. <i>Cancer Chemotherapy and Pharmacology</i> , 2019, 84, 1257-1267.	2.3	58
4	First-in-Human Phase I Study to Evaluate the Brain-Penetrant PI3K/mTOR Inhibitor GDC-0084 in Patients with Progressive or Recurrent High-Grade Glioma. <i>Clinical Cancer Research</i> , 2020, 26, 1820-1828.	7.0	54
5	A phase IB dose-escalation study of the safety and pharmacokinetics of pictilisib in combination with either paclitaxel and carboplatin (with or without bevacizumab) or pemetrexed and cisplatin (with or without bevacizumab) in patients with recurrent high-grade glioma. <i>Journal of Clinical Oncology</i> , 2018, 36, 186-196.	2.8	28
6	Investigation of the absolute bioavailability and human mass balance of navoximod, a novel IDO1 inhibitor. <i>British Journal of Clinical Pharmacology</i> , 2019, 85, 1751-1760.	2.4	15